Clinical Trials

Breast Neoplasms

NCT05879926 2026-05-07

OFSET

Phase 3 Recruiting

3,960 enrolled

Breast Neoplasms

NCT07400523 2026-04-28

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

446 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

156 enrolled

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

180 enrolled 14 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

984 enrolled

Hot Flashes

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT05700006 2026-03-05

BETA

94 enrolled

Arthralgia

NCT02767661 2026-02-27

MECCA

263 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT03624244 2026-02-17

BFR-ESS

Phase NA Not yet recruiting

40 enrolled

Gynecologic

Endometrial Stromal Tumors

NCT07379502 2026-01-30

Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate

60 enrolled

Polycystic Ovary Syndrome

NCT06534125 2026-01-29

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Phase NA Recruiting

150 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06970912 2026-01-21

DNADalHR

393 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

44 enrolled

Hormone Receptor Positive Breast Carcinoma

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

14 enrolled

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06361940 2025-10-14

MAPPER

100 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT04227327 2025-07-29

HERMIONE-7

Phase 2 Terminated

31 enrolled

Advanced Breast Cancer

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

2,508 enrolled

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

300 enrolled

Breast Neoplasms

NCT05190094 2025-05-07

ICRG0201

80 enrolled

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast Neoplasms

NCT05012644 2024-10-08

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

197 enrolled 16 charts

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05361655 2024-06-07

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

2,888 enrolled 17 charts

Breast Neoplasms

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Phase 3 Recruiting

184 enrolled

Advanced Breast Cancer

NCT05043506 2024-03-27

EUCHARIS

1,939 enrolled

Breast Neoplasms

NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

2 enrolled 13 charts

Estrogen Receptor and/or Progesterone Receptor Positive

NCT04240106 2024-02-16

LUZERN

14 enrolled

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

265 enrolled

Breast Neoplasms

NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Phase 2 Unknown

30 enrolled

Luminal B/HER2-negative Breast Cancer

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

17 enrolled 5 charts

Breast Neoplasms

NCT03917082 2023-06-15

LALEAST

290 enrolled

Breast Cancer Female

NCT05801705 2023-05-18

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Unknown

700 enrolled

Hormone-receptor-positive Breast Cancer

NCT03462251 2023-01-19

RIBBIT

41 enrolled